Investing in the future

There has never been a greater need for advanced organ preservation solutions, and the need is growing. More than 200,000 patients in Europe and the US await lifesaving organ transplants. Although there has been a general increase in the availability of donor organs due to extensive educational programmes, UK transplant statistics show a slight decline in the number of donor organs, and transplants have fallen for the first time in many years. The requirement for organ transplantation will continue to rise based on an aging global society, and an increase in the number of chronic diseases and organ failure worldwide. It is more important than ever to ensure that each organ is afforded the best preservation solution possible. 

OPSL are well placed to make a dramatic impact in the organ preservation field with two advanced cold static organ preservation solutions (LS-A™ and LS-T™), which have outperformed current ‘Gold Standard’ solutions in all pre-clinical trials. We are working closely with the NHS as a platform for a worldwide launch. Our solutions’ improved handling due to lower viscosity is seen as an important lever in the rapid uptake by surgeons and healthcare providers. Further to this, we have a strong IP position with a newly filed patent providing the potential of a further 20 years of patent life and further IP to support product expansion across the transplant area. We have advanced strategic partnership discussions with key players in multiple markets, suggesting diverse options for OPSL’s future.

Current Investors


Medipex is a healthcare innovation hub connecting the NHS with industry and academia, sharing knowledge of the NHS and commercialisation processes to facilitate the innovation cycle. Medipex has extensive knowledge of the changing NHS landscape and is skilled at discovering and evaluating ideas for the benefit of patients, clinicians and NHS Trusts. Medipex has incubated OPSL’s technology over several years, secured the Intellectual Property and, together with Brightstar Partners, raised investment to complete the development programme and ultimately commercialise the lead products.

Brightstar Partners

Brightstar Partners are an international venture capital and venture development firm who specialise in commercialising cutting-edge medical technology, by getting hands-on at the very early stages and helping navigate the pathway from the lab to the market. Their focus is on institutional spinouts or entities with a strong connection to a corporate or institutional R+D facility. The Korean UK Innovation fund-I (KUKI-I) managed by Brightstar Partners completed its first investment in the UK, and OPSL was incorporated in January 2016 with this investment.

Future Company Development

As OPSL progresses strongly with its initial products, the management and board see enormous potential for growth and diversification across the wider organ transplant field. We are building on extensive (20+ years) R+D within the NHS and intend to maximise our return on the extensive IP being produced.



The core technology is extensively protected. A full freedom-to-operate search has been conducted. 

Patent numbers EP/1339280; WO/0241696; CA/2427325; US/2004053205. 

New improvement patents have been filed in 2017 extending the patent life of LS-A™ by a further 20 years.

Preparing for an ageing population is integral to the achievement of many of the sustainable development goals

United Nations: World Population Ageing Report 2015, P100

slide 1
slide 2
slide 3
slide 4

The shifting demographic toward an older population creates increased pressure on healthcare systems, as well as several medical product opportunities; "Preparing for an aging population is integral to the achievement of many of the sustainable development goals” United Nations: World Population Ageing Report 2015, P100 - World Health Organisation 2015